# Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

> **NCT02836496** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 108 (actual)

## Conditions studied

- Hypereosinophilic Syndrome

## Interventions

- **DRUG:** Mepolizumab 300 mg
- **DRUG:** Placebo matching mepolizumab
- **DRUG:** Active OCS capsules (5 mg prednisolone or prednisone)
- **DRUG:** Placebo matching OCS capsules

## Key facts

- **NCT ID:** NCT02836496
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-07
- **Primary completion:** 2019-08-08
- **Final completion:** 2019-08-08
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2020-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02836496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02836496, "Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02836496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*